Based on presentations and an expert panel at Cure JM’s January 2026 Virtual Summit on JIIM Research & Care
At the January 2026 Cure JM Virtual Summit, pediatric rheumatology experts shared updates on new treatments for juvenile dermatomyositis (JDM). While the presentations were intended for medical professionals, this summary translates the findings for families. One of the most promising therapies discussed was anifrolumab, a monoclonal antibody that targets a specific part of the immune system called the type I interferon pathway.
Many children with JDM continue to have persistent skin rashes and sensitivity to sunlight, even when their muscle symptoms improve. Dr. Grace Osborne highlighted that the interferon pathway is often highly active in the skin, contributing to these symptoms. This is important because anifrolumab works by blocking this pathway, potentially helping skin symptoms that do not respond well to standard treatments.
The Case Example: Anifrolumab in Action
During the expert panel, Dr. Rebecca Hetrick described a child with JDM whose disease was refractory, meaning it did not respond fully to standard therapies including steroids, methotrexate, IVIG, hydroxychloroquine, and tofacitinib. Despite months of treatment, the child continued to have painful, itchy, and ulcerated rashes, as well as persistent fatigue and discomfort.
After starting anifrolumab, the child experienced a dramatic improvement in skin comfort and appearance, reporting the best quality of life since diagnosis. Steroid doses were gradually reduced, showing the therapy’s potential steroid-sparing effect. This aligns with Dr. Osborne’s observation that targeting interferon may allow for lower steroid use without compromising disease control.
However, the child developed persistent leukopenia, a lower-than-normal white blood cell count. While experts are still investigating whether this is caused by anifrolumab, the panel emphasized careful monitoring of blood counts, liver function, and infection risk (echoing Dr. Osborne’s guidance that new therapies require close clinical supervision.)
Why the Interferon Pathway Matters
Type I interferon is a key part of the immune system that can become overactive in JDM.
- It helps trigger inflammation in skin and muscles.
- Blocking interferon with anifrolumab may reduce skin rashes and other autoimmune activity.
- Early data suggest this could allow safer reduction of steroids while maintaining disease control.
Key Takeaways for Families
- Anifrolumab is a new monoclonal antibody therapy being studied in children with JDM who have refractory disease.
- It works by blocking the type I interferon pathway, which is often overactive in the skin and immune system.
- Early cases suggest it can improve skin symptoms and allow reduction of steroid doses.
- Careful monitoring is essential, particularly for white blood cell counts and liver health.
- Participation in clinical trials may give access to this therapy under expert supervision. Details are available on the Cure JM clinical trials page.
Looking Ahead
Anifrolumab represents an exciting step in targeted therapy for JDM, especially for children whose skin and other symptoms do not respond to conventional treatments. Families should understand that the therapy is still investigational, and clinical trials will continue to determine the safest and most effective dosing in children.
For Educational Purposes Only
This article summarizes information presented at the Cure JM Virtual Medical Summit. It is not medical advice or a treatment recommendation. Anifrolumab is investigational and not approved for general use in children. Families should always discuss treatment options with their child’s healthcare provider.
